Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 34, 2016, Pages 9587-9592

  Wang, Wei ^a   Nguyen, Linh T T ^a   Burlak, Christopher ^b   Chegini, Fariba ^c   Guo, Feng ^c   Chataway, Tim ^c   Ju, Shulin ^d,k   Fisher, Oriana S ^d,l   Miller, David W ^e   Datta, Debajyoti ^f   Wu, Fang ^d,m   Wu, Chun Xiang ^a   Landeru, Anuradha ^a   Wells, James A ^f,g   Cookson, Mark R ^e   Boxer, Matthew B ^h   Thomas, Craig J ^h   Gai, Wei Ping ^c   Ringe, Dagmar ^d,i,j   Petsko, Gregory A ^d,i,j,n   Hoang, Quyen Q ^a   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c FLINDERS UNIVERSITY   (Australia)

^d BRANDEIS UNIVERSITY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k WRIGHT STATE UNIVERSITY   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

Aggregation; Caspase; Inflammasome; Parkinson's disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; SHORT HAIRPIN RNA; 1-(2-((1-(4-AMINO-3-CHLOROPHENYL)METHANOYL)AMINO)-3,3-DIMETHYLBUTANOYL)PYRROLIDINE-2-CARBOXYLIC ACID; 4 AMINOBENZOIC ACID DERIVATIVE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; DIPEPTIDE; IL1B PROTEIN, HUMAN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MENADIONE; NIGERICIN; PROTEIN AGGREGATE; SMALL INTERFERING RNA; SNCA PROTEIN, HUMAN;

ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; LEWY BODY; NERVE CELL; NERVE CELL CULTURE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; ALUM COMPOUNDS; CASPASE 1; CELL LINE, TUMOR; CELL SURVIVAL; DIPEPTIDES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMASOMES; INTERLEUKIN-1BETA; LEWY BODIES; LIPOPOLYSACCHARIDES; NEURONS; NIGERICIN; PARA-AMINOBENZOATES; PROTEIN AGGREGATES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VITAMIN K 3;

EID: 84983688506     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1610099113     Document Type: Article

References (57)

1. Ben-Shlomo Y (1997) The epidemiology of Parkinson's disease.Baillieres Clin Neurol 6(1):55-68.
2. Tanner CM, et al. (2011) Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 119(6):866-872.
3. Lang AE, Lozano AM (1998) Parkinson's disease. N Engl J Med 339:1130-1143.
4. Gavett BE, Stern RA, Cantu RC, Nowinski CJ, McKee AC (2010) Mild traumatic brain injury: A risk factor for neurodegeneration. Alzheimers Res Ther 2(3):18.
5. McKee AC, et al. (2009) Chronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 68(7):709-735.
6. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10(Suppl 1):S3-S7.
7. Arai H, Furuya T, Mizuno Y, Mochizuki H (2006) Inflammation and infection in Parkinson's disease. Histol Histopathol 21(6):673-678.
8. Harris MA, Tsui JK, Marion SA, Shen H, Teschke K (2012) Association of Parkinson's disease with infections and occupational exposure to possible vectors. Mov Disord 27(9):1111-1117.
9. Rail D, Scholtz C, Swash M (1981) Post-encephalitic Parkinsonism: Current experience. J Neurol Neurosurg Psychiatr 44(8):670-676.
10. Henry J, Smeyne RJ, Jang H, Miller B, Okun MS (2010) Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord 16(9):566-571.
11. Jang H, et al. (2009) Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA 106(33):14063-14068.
12. Maurizi CP (1985) Why was the 1918 influenza pandemic so lethal? The possible role of a neurovirulent neuraminidase. Med Hypotheses 16(1):1-5.
13. Oueslati A, Fournier M, Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: Implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 183:115-145.
14. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci27(12):3338-3346.
15. Michell AW, et al. (2007) The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant 16(5):461-474.
16. Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci 32(3):409-422.
17. Wakamatsu M, et al. (2008) Selective loss of nigral dopamine neurons induced by over-expression of truncated human alpha-synuclein in mice. Neurobiol Aging 29(4):574-585.
18. Prasad K, Beach TG, Hedreen J, Richfield EK (2012) Critical role of truncated α-synuclein and aggregates in Parkinson's disease and incidental Lewy body disease. Brain Pathol 22(6):811-825.
19. Li W, et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 102(6):2162-2167.
20. Iwata A, et al. (2003) Alpha-synuclein degradation by serine protease neurosin: Implication for pathogenesis of synucleinopathies. Hum Mol Genet 12(20):2625-2635.
21. Lewis KA, Yaeger A, DeMartino GN, Thomas PJ (2010) Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations. J Bioenerg Biomembr 42(1):85-95.
22. Lewis KA, et al. (2010) Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology. Am J Pathol 177(6):3037-3050.
23. Mishizen-Eberz AJ, et al. (2003) Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J Neurochem 86(4):836-847.
24. Sung JY, et al. (2005) Proteolytic cleavage of extracellular secreted alpha-synuclein via matrix metalloproteinases. J Biol Chem 280(26):25216-25224.
25. Sevlever D, Jiang P, Yen SH (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47(36):9678-9687.
26. Vanaja SK, Rathinam VAK, Fitzgerald KA (2015) Mechanisms of inflammasome activation: Recent advances and novel insights. Trends Cell Biol 25(5):308-315.
27. Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302(5651):1772-1775.
28. Li W, et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 102(6):2162-2167.
29. Scheer JM, Wells JA, Romanowski MJ (2005) Malonate-assisted purification of human caspases. Protein Expr Purif 41(1):148-153.
30. Boxer MB, et al. (2010) A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. ChemMedChem 5(5):730-738.
31. Wang W, et al. (2011) A soluble α-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci USA 108(43):17797-17802.
32. Oh M, et al. (2014) Potential pharmacological chaperones targeting cancer-Associated MCL-1 and Parkinson disease-associated α-synuclein. Proc Natl Acad Sci USA 111(30):11007-11012.
33. Michell AW, et al. (2007) The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant 16(5):461-474.
34. Liu CW, et al. (2005) A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: Implications for pathogenesis of Parkinson disease. J Biol Chem 280(24):22670-22678.
35. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 10(Suppl 1):S3-S7.
36. McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 76(6):550-557.
37. Bartels AL, Leenders KL (2007) Neuroinflammation in the pathophysiology of Parkinson's disease: Evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord 22(13):1852-1856.
38. Blum-Degen D, et al. (1995) Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202(1-2):17-20.
39. Mogi M, et al. (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211(1):13-16.
40. Mogi M, et al. (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165 (1-2):208-210.
41. Mogi M, et al. (1994) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180(2):147-150.
42. Villoslada P, et al. (2008) Immunotherapy for neurological diseases. Clin Immunol 128(3):294-305.
43. Schwartz M, Butovsky O, Kipnis J (2006) Does inflammation in an autoimmune disease differ from inflammation in neurodegenerative diseases? Possible implications for therapy. J Neuroimmune Pharmacol 1(1):4-10.
44. Dinarello CA (2006) Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr 83(2):447S-455S.
45. Tanner CM, et al. (2011) Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect 119(6):866-872.
46. Knoblach SM, et al. (2002) Multiple caspases are activated after traumatic brain injury: evidence for involvement in functional outcome. J Neurotrauma 19(10):1155-1170.
47. Furuya T, et al. (2004) Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 24(8):1865-1872.
48. Cullen V, et al. (2011) Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol 69(6):940-953.
49. Liu B, Gao HM, Hong JS (2003) Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: Role of neuroinflammation. Environ Health Perspect 111(8):1065-1073.
50. Klevenyi P, et al. (1999) Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 10(3):635-638.
51. Ling Z, et al. (2002) In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 17(1):116-124.
52. Gao H-M, et al. (2011) Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. Environ Health Perspect 119(6):807-814.
53. Liu B, Gao HM, Hong JS (2003) Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: Role of neuroinflammation. Environ Health Perspect 111(8):1065-1073.
54. Klevenyi P, et al. (1999) Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport 10(3):635-638.
55. Ling Z, et al. (2002) In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 17(1):116-124.
56. Du Y, et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98(25):14669-14674.
57. Bassil F, et al. (2016) Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy. Proc Natl Acad Sci USA 113:9593-9598.